Foresite Capital Fund IV, L.P. 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-05-10 5:20 pm Purchase |
2023-05-08 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 13,718,311 29.500% |
1,780,000 (+14.91%) |
Filing |
| 2023-02-22 3:01 pm Purchase |
2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 11,938,311 25.600% |
1,100,000 (+10.15%) |
Filing |
| 2020-12-14 9:24 pm Purchase |
2020-12-03 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 10,838,311 25.000% |
10,838,311 (New Position) |
Filing |